On Monday, Banro Corporation (USA) (NYSEMKT:BAA)’s shares declined -2.04% to $0.197.
Banro Corporation (USA) (BAA) declared its financial and operating results for the full year 2014 and fourth quarter 2014.
FINANCIAL HIGHLIGHTS
Record 2014 revenue of $125.4 million, a 12% raise over 2013 ($111.8 million); Q4 2014 revenue of $35 million, a 30% raise over the previous year’s quarter.
Gross earnings from operations of $29.4 million, a 55% raise over 2013 ($19 million).
Twangiza EBITDA of $44.8 million vs 2013 of $34.3 million for a 31% improvement
$90+ million financing signed subsequent to year end.
Banro Corporation, together with its auxiliaries, engages in the exploration, development, and production of mineral properties. It primarily explores for gold. The company holds a 100% interest in four gold properties, counting Twangiza, Namoya, Lugushwa, and Kamituga comprising 13 exploitation permits that cover an area of about 2,612 square kilometers in the South Kivu and Maniema provinces of the Democratic Republic of the Congo.
Companhia de Saneamento Basico (ADR) (NYSE:SBS)’s shares dropped -1.53% to $5.81.
Companhia de Saneamento Basico (ADR) (SBS) (BM&FBovespa: SBSP3; NYSE: SBS), following CVM Instruction 358 of January 3rd, 2002, and amendments thereto, hereby declares that, in regard to the Material Fact of March 31, 2015, which stated that the Sao Paulo State Sanitation and Energy Regulatory Agency (“ARSESP) had, on that date, presented for Public Consultation a proposal for a Sabesp Extraordinary Tariff Revision, in accordance with Preliminary Technical Note RTS/003/2015, the total raise in the tariff projected by the agency is 13.87% and not 13.97%, as revealed formerly.
Companhia de Saneamento Básico do Estado de São PauloSABESP provides basic and environmental sanitation services; and supplies treated water on a wholesale basis to residential, commercial, industrial, and governmental customers in the state of São Paulo.
At the end of Monday’s trade, Cemex SAB de CV (ADR) (NYSE:CX)‘s shares dipped -1.52% to $9.73.
Cemex SAB de CV (ADR) (CX) declared recently that it will report its first quarter 2015 results on Thursday, April 23, 2015.
CLH will host a conference call and webcast presentation on this same date at 11:30 AM ET to talk about these results.
CEMEX, S.A.B. de C.V., a building materials company, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, and other construction materials in Mexico, the United States, Northern Europe, the Mediterranean, South America, the Caribbean, and Asia.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended its Monday’s trading session with -1.51% loss, and closed at $4.57.
Arena Pharmaceuticals, Inc. (ARNA) declared the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as contrast to the twice-daily immediate release formulation approved by the US Food and Drug Administration (FDA) and marketed as BELVIQ®. If approved, the extended release formulation is predictable to be marketed as BELVIQ XR, which is the brand name conditionally approved by the FDA.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
